OTCPK:RHCG.F

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Ryman Healthcare Limited develops, owns, and operates integrated retirement villages, rest homes, and hospitals for the elderly in New Zealand and Australia. More Details


Snowflake Analysis

Established dividend payer with limited growth.


Similar Companies

Share Price & News

How has Ryman Healthcare's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: RHCG.F has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

RHCG.F

-2.3%

US Healthcare

-0.8%

US Market


1 Year Return

n/a

RHCG.F

21.0%

US Healthcare

13.8%

US Market

Return vs Industry: Insufficient data to determine how RHCG.F performed against the US Healthcare industry.

Return vs Market: Insufficient data to determine how RHCG.F performed against the US Market.


Shareholder returns

RHCG.FIndustryMarket
7 Day0%-2.3%-0.8%
30 Day0%-4.3%-5.0%
90 Dayn/a1.8%10.1%
1 Yearn/a22.6%21.0%16.4%13.8%
3 Year12.6%12.6%23.9%18.5%36.9%27.8%
5 Yearn/a50.1%39.4%85.0%64.2%

Price Volatility Vs. Market

How volatile is Ryman Healthcare's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Ryman Healthcare undervalued compared to its fair value and its price relative to the market?

26.18x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: RHCG.F ($7.6) is trading above our estimate of fair value ($3.31)

Significantly Below Fair Value: RHCG.F is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: RHCG.F is poor value based on its PE Ratio (26.2x) compared to the US Healthcare industry average (22.2x).

PE vs Market: RHCG.F is poor value based on its PE Ratio (26.2x) compared to the US market (17.6x).


Price to Earnings Growth Ratio

PEG Ratio: RHCG.F is poor value based on its PEG Ratio (2x)


Price to Book Ratio

PB vs Industry: RHCG.F is overvalued based on its PB Ratio (3x) compared to the US Healthcare industry average (2.8x).


Next Steps

Future Growth

How is Ryman Healthcare forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

13.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: RHCG.F's forecast earnings growth (13.2% per year) is above the savings rate (2.2%).

Earnings vs Market: RHCG.F's earnings (13.2% per year) are forecast to grow slower than the US market (22.9% per year).

High Growth Earnings: RHCG.F's earnings are forecast to grow, but not significantly.

Revenue vs Market: RHCG.F's revenue (11.2% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: RHCG.F's revenue (11.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: RHCG.F's Return on Equity is forecast to be low in 3 years time (14%).


Next Steps

Past Performance

How has Ryman Healthcare performed over the past 5 years?

3.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: RHCG.F has a large one-off gain of NZ$144.4M impacting its March 31 2020 financial results.

Growing Profit Margin: RHCG.F's current net profit margins (62.5%) are lower than last year (85.4%).


Past Earnings Growth Analysis

Earnings Trend: RHCG.F's earnings have grown by 3% per year over the past 5 years.

Accelerating Growth: RHCG.F's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: RHCG.F had negative earnings growth (-18.8%) over the past year, making it difficult to compare to the Healthcare industry average (31.1%).


Return on Equity

High ROE: RHCG.F's Return on Equity (11.5%) is considered low.


Next Steps

Financial Health

How is Ryman Healthcare's financial position?


Financial Position Analysis

Short Term Liabilities: RHCG.F's short term assets (NZ$470.5M) do not cover its short term liabilities (NZ$697.0M).

Long Term Liabilities: RHCG.F's short term assets (NZ$470.5M) do not cover its long term liabilities (NZ$4.7B).


Debt to Equity History and Analysis

Debt Level: RHCG.F's debt to equity ratio (76.7%) is considered high.

Reducing Debt: RHCG.F's debt to equity ratio has increased from 37.5% to 76.7% over the past 5 years.

Debt Coverage: RHCG.F's debt is well covered by operating cash flow (25.5%).

Interest Coverage: RHCG.F's interest payments on its debt are not well covered by EBIT (2.4x coverage).


Balance Sheet


Next Steps

Dividend

What is Ryman Healthcare current dividend yield, its reliability and sustainability?

1.75%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: RHCG.F's dividend (1.75%) is higher than the bottom 25% of dividend payers in the US market (1.72%).

High Dividend: RHCG.F's dividend (1.75%) is low compared to the top 25% of dividend payers in the US market (4.94%).


Stability and Growth of Payments

Stable Dividend: RHCG.F's dividends per share have been stable in the past 10 years.

Growing Dividend: RHCG.F's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (45.7%), RHCG.F's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: RHCG.F's dividends in 3 years are forecast to be well covered by earnings (50% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.2yrs

Average management tenure


CEO

Gordon MacLeod

3.17yrs

Tenure

NZ$1,356,641

Compensation

Mr. Gordon MacLeod has been the Chief Executive Officer since July 1, 2017 of Ryman Healthcare Limited since October 26, 2006 and serves as its Secretary and served as its Deputy Chief Executive and Chief ...


CEO Compensation Analysis

Compensation vs Market: Gordon's total compensation ($USD888.03K) is below average for companies of similar size in the US market ($USD5.74M).

Compensation vs Earnings: Gordon's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Gordon MacLeod
CEO & Secretary3.17yrsNZ$1.36m0.14%
NZ$ 6.2m
David Bennett
Chief Financial Officer3.25yrsno data0.031%
NZ$ 1.4m
Cheyne Chalmers
Chief Operations Officer0.67yrno data0.0085%
NZ$ 383.0k
Nicole Forster
Chief People & Technology Officer1.67yrsno data0.022%
NZ$ 973.2k
Mary-Anne Stone
Acting Chief of Sales & Marketing Officer0.67yrno data0.0048%
NZ$ 215.2k
Jeremy Moore
Chief Development Officer0.67yrno data0.018%
NZ$ 813.4k
David King
Corporate Affairs Managerno datano datano data
Michelle Perkins
Investor Relations Managerno datano datano data

1.2yrs

Average Tenure

Experienced Management: RHCG.F's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
David Kerr
Independent Chairman of the Board21.67yrsNZ$222.00k0.072%
NZ$ 3.2m
Simon Challies
Advisor to the Board3.33yrsNZ$2.73mno data
George Savvides
Independent Non-Executive Director7.67yrsNZ$136.25k0.011%
NZ$ 490.0k
Warren Bell
Independent Deputy Chairmanno dataNZ$128.50k0.00030%
NZ$ 13.5k
Jo Appleyard
Independent Non-Executive Director11.67yrsNZ$110.50k0.016%
NZ$ 714.2k
Claire Higgins
Independent Non-Executive Director6yrsNZ$136.25k0.0031%
NZ$ 139.9k
Paula Jeffs
Independent Director0.83yrNZ$38.68kno data
Anthony Leighs
Independent Director1.92yrsNZ$128.50k0.0020%
NZ$ 90.7k
Geoffrey Cumming
Director2.25yrsNZ$110.50kno data

4.7yrs

Average Tenure

Experienced Board: RHCG.F's board of directors are considered experienced (4.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: RHCG.F insiders have sold more shares than they have bought in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Ryman Healthcare Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Ryman Healthcare Limited
  • Ticker: RHCG.F
  • Exchange: OTCPK
  • Founded: 1984
  • Industry: Health Care Facilities
  • Sector: Healthcare
  • Market Cap: NZ$6.892b
  • Listing Market Cap: NZ$4.512b
  • Shares outstanding: 497.29m
  • Website: https://www.rymanhealthcare.co.nz

Number of Employees


Location

  • Ryman Healthcare Limited
  • Airport Business Park
  • 92 Russley Road
  • Christchurch
  • 8042
  • New Zealand

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RYMNZSE (New Zealand Stock Exchange)YesOrdinary SharesNZNZDJun 1999
RHCG.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJun 1999
RH7DB (Deutsche Boerse AG)YesOrdinary SharesDEEURJun 1999
RYHT.YOTCPK (Pink Sheets LLC)UNSPONSORED ADRUSUSDNov 2011

Biography

Ryman Healthcare Limited develops, owns, and operates integrated retirement villages, rest homes, and hospitals for the elderly in New Zealand and Australia. Its villages offer a range of retirement living ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/27 05:54
End of Day Share Price2020/07/06 00:00
Earnings2020/03/31
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.